Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders

J Clin Endocrinol Metab. 2021 Jan 1;106(1):226-236. doi: 10.1210/clinem/dgaa686.

Abstract

Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. Deiodination of amiodarone releases large amounts of iodine that can impair thyroid function, causing either hypothyroidism or thyrotoxicosis in susceptible individuals reflecting ~20% of patients administered the drug. Not only the excess iodine, but also the amiodarone (or its metabolite, desethylamiodarone) itself may cause thyroid dysfunction by direct cytotoxicity on thyroid cells. We present an overview of the epidemiology and pathophysiology of amiodarone-induced thyroid disorders, with a focus on the various forms of clinical presentation and recommendations for personalized management of each form.

Keywords: amiodarone; hypothyroidism; management; thyroid; thyroiditis; thyrotoxicosis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Albania
  • Amiodarone / adverse effects*
  • Arrhythmias, Cardiac / drug therapy
  • Arrhythmias, Cardiac / etiology
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Myocardial Infarction / drug therapy
  • Thyroid Diseases / chemically induced*
  • Thyroid Diseases / diagnosis
  • Thyroid Diseases / therapy*
  • Thyroid Function Tests

Substances

  • Amiodarone